Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Unknown 2Recruiting 2Completed 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 15Neoplasms 2NSCLC 2Breast Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Sexual Dysfunction, Physiological 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Small Cell Lung Cancer With EGFR Mutation 1Non Small Cell Lung Cancer Metastatic 1NSCLC Patients With Brain Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma 1Meningeal Carcinomatosis 1Lung Cancer Metastatic 1Locally Advanced or Metastatic Non-squamous NSCLC 1Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Eunuchism 1Erectile Dysfunction 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

Magnetic Resonance Spectroscopy 23Radiosurgery 21Temozolomide 14Bevacizumab 12pembrolizumab 10Specimen Handling 9Nivolumab 8Radiotherapy 7Ipilimumab 7Magnetic Resonance Imaging 6Cyclophosphamide 5Capecitabine 5Blood Specimen Collection 5encorafenib 4Radiation 4Neuropsychological Tests 4Mental Status and Dementia Tests 4Memantine 4Carboplatin 4fludarabine 3fluciclovine F-18 3binimetinib 3abemaciclib 3Watchful Waiting 3Proton Therapy 3Etoposide 3Dexamethasone 3Adrenal Cortex Hormones 3trastuzumab deruxtecan 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Brain Neoplasms × osimertinib × Clear all
NCT07206498 2025-11-28

WAYWIN103

Wayshine Biopharm, Inc.

Phase 1/2 Recruiting
48 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05948813 2024-11-21

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

TYK Medicines, Inc

Phase 2 Recruiting
420 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡